Data from EMC - Curated by Toby Galbraith - Last updated 19 May 2017

Licensing authority

EMA (European Medicines Agency)

Indication(s)

Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency).

AFSTYLA can be used for all age groups.

Full Prescribing information

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Oral Anticoagulation Reversal

Experts discuss the use of non-vitamin K oral anticoagulants in the treatment and prevention of stroke, deep vein thrombosis and pulmonary embolism in atrial fibrillation patients

Visit Oral Anticoagulation Reversal


Obesity

Learn about the complex factors influencing development of obesity

Visit Obesity


Related Content

More information

Category Value
Agency product number EMEA/H/C/004075
Orphan designation No
Date First Approved 04-01-2017
Type Medicinal product subject to restricted medical prescription
Marketing authorisation holder CSL Behring GmbH